JAZZ - Jazz Pharmaceuticals Public Limited Company

NasdaqGS - NasdaqGS Delayed Price. Currency in USD

Jazz Pharmaceuticals Public Limited Company

Connaught House
Fourth Floor
Dublin 4
Ireland
353 1 634 7800
http://www.jazzpharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees1,110

Key Executives

NameTitlePayExercisedAge
Mr. Bruce C. CozaddCo-Founder, Exec. Chairman & Chief Exec. Officer1.84MN/A53
Mr. Matthew P. YoungExec. VP & CFO817.79kN/A48
Mr. Russell J. CoxExec. VP & COO889.98kN/A54
Ms. Suzanne Sawochka HooperExec. VP & Gen. Counsel826.78kN/A51
Dr. Karen Smith M.D., PH.D., M.B.A., L.L.MChief Medical Officer and Exec. VP of R&D745.85kN/A49
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops JZP-110, which is in phase III clinical trial for the treatment of excessive sleepiness (ES) in patients with narcolepsy and obstructive sleep apnea, as well as phase II clinical trial for ES associated with Parkinson’s disease; Vyxeos (CPX-351) for high-risk acute myeloid leukemia; and JZP-507 and JZP-258 to treat EDS and cataplexy in narcolepsy, as well as evaluates deuterated oxybate for narcolepsy. In addition, it sells psychiatry and other products. The company is headquartered in Dublin, Ireland.

Corporate Governance

Jazz Pharmaceuticals Public Limited Company’s ISS Governance QualityScore as of November 1, 2017 is 9. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 10; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.